Home » Pipeline
Pipeline
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
| COVID-19 Trials and Actions | |||
| Eli Lilly Junshi Biosciences |
bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) | mild-to-moderate COVID-19 in patients age 12 and older who are at high risk for progressing to severe COVID-19 and/or hospitalization | Emergency Use Authorization (EUA) granted by the FDA |
| GenScript USA | cPass SARS-CoV-2 Neutralization Antibody Detection Kit in convalescent plasma screening | detection of COVID-19 neutralizing antibodies without the use of live virus | EUA granted by the FDA |
| Other Trials and Actions | |||
| Adaptive Phage Therapeutics | PhageBank therapy | prosthetic joint infections | IND approved by the FDA |
| Catapult Therapeutics | CAP-100 | hematological malignancies | IND approved by the FDA |
| Ideaya Biosciences | IDE397 | solid tumors harboring MTAP deletion | IND approved by the FDA |
| ImmunoMet Therapeutics | IM156 | idiopathic pulmonary fibrosis | IND approved by the FDA |
| Intrommune Therapeutics | INT301, oral mucosal immunotherapy | peanut allergies | IND approved by the FDA |
| NeurMedix | NE3107 | mild-to-moderate Alzheimer’s disease | IND approved by the FDA for phase 3 trial |
| Passage Bio | PBKR03 | early infantile Krabbe disease (globoid cell leukodystrophy) | IND approved by the FDA |
| Triastek | T19 3D printed formulation | rheumatoid arthritis | IND approved by the FDA |
| I-Mab Morphosys |
TJ210/MOR210 | advanced solid tumors | IND approved by the China National Medical Products Administration |
| Celon Pharma | CPL’116 | autoimmune diseases | completion of phase 1a trial |
| Cue Biopharma | CUE-101 in combination with Keytruda (pembrolizumab) | first-line treatment for HPV+ recurrent/metastatic head and neck squamous-cell carcinoma | first patient dosed in phase 1 trial |
| Curis | CA-4948 in combination with ibrutinib | relapsed or refractory hematologic malignancies | first patient dosed in phase 1 trial |
| Melt Pharmaceuticals | Melt technology (midazolam 3 mg/ketamine 25 mg and midazolam 6 mg/ketamine 50 mg) | sedation and analgesia for patients undergoing cataract surgery | completion of phase 1 trial |
| Tessa Therapeutics | TT11X – allogeneic CD30-CAR Epstein Barr virus-specific T-cell therapy | CD30+ lymphoma | completion of dosing in first patient cohort in phase 1 trial |
| Regulus Therapeutics | RGLS4326 | autosomal dominant polycystic kidney disease | completion of patient enrollment in first cohort of phase 1b trial |
| Vaccitech | VTP-300 with and without a low-dose anti-PD-1 antibody | chronic hepatitis B infection | first patient dosed in phase 1b/2a trial |
| Gemini Therapeutics | GEM103 | dry age-related macular degeneration with complement factor H (CFH) and loss-of-function gene variants | completion of patient enrollment in phase 2a trial |
| Brooklyn Immunotherapeutics | IRX-2 in combination with pembrolizumab (Keytruda) and chemotherapy | triple-negative breast cancer | initiation of phase 2 trial |
| Trefoil Therapeutics | TTHX1114 | Fuchs endothelial corneal dystrophy | initiation of phase 2 trial |
| Navidea Biopharmaceuticals | NAV3-32 | rheumatoid arthritis | initiation of phase 2b trial |
| Evolve Biologic | PlasmaCap IG (intravenous immunoglobulin) | adults and children with primary immune deficiency disease | completion of phase 3 trial |
| Innovent Biologics | IBI310 in combination with Tyvyt (sintilimab) injection | first-line treatment of advanced hepatocellular carcinoma | first patient dosed in phase 3 trial |
| ImmunoMet Therapeutics | IM156 | idiopathic pulmonary fibrosis | Orphan Drug designation granted by the FDA |
| Vascular Perfusion Solutions | VP.S Encore oxygenated perfusion cardiac transport device | preservation of vascularized tissue | Breakthrough Device designation granted by the FDA |
| Puzzle Medical Devices | minimally invasive transcatheter heart pump | heart failure | Breakthrough Device designation granted by the FDA |
| Allergan | Botox (onabotulinumtoxinA) | detrusor overactivity associated with a neurologic condition in patients age five and older who have an inadequate response to or are intolerant of anticholinergic medication | approved by the FDA for additional indication |
| Bristol Myers Squibb/Juno Therapeutics | Breyanzi (lisocabtagene maraleucel) | patients with certain types of large B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment | approved by the FDA |
| Regeneron Sanofi |
Libtayo (cemiplimab-rwlc) | locally advanced and metastatic basal cell carcinoma | approved by the FDA |
| Rhizen Pharmaceuticals TG Therapeutics |
Ukoniq (umbralisib) | relapsed or refractory marginal-zone lymphoma and follicular lymphoma | accelerated approval granted by the FDA |
| Signifier Medical Technologies | eXciteOSA daytime intraoral neuromuscular stimulation device | mild obstructive sleep apnea and snoring | approved by the FDA |
Upcoming Events
-
25May
-
28Jun
-
16Oct
